AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
BioVie Inc.
Video analysis: BIVI
All videosNo video analysis for this stock yet. Request one from our team.
News: BIVI
Dow closes sharply lower as oil surge fuels inflation fears
4:15pm: Oil spike hits stocks US stocks closed sharply lower on Tuesday as surging oil prices revived inflation worries and pushed investors to reassess the...
BioVie advances Parkinson's Phase 3 development program with FDA engagement
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) told investors that it is preparing to advance its Phase 3 development program for bezisterim in Parkinson's disease and has requested an End-of-Phase 2 meeting with the US Food and Drug Administration. The company is working with Parkinson's disease clinical development experts to finalize the design of a Phase 3 trial.
BioVie Announces Update to Parkinson's Phase 3 Development Program
Company Corresponded with the FDA on an End of Phase 2 Meeting to Align on Phase 3 trial Design for Evaluation of Bezisterim in Early-stage Parkinson's Disease Company Corresponded with the FDA on an End of Phase 2 Meeting to Align on Phase 3 trial Design for Evaluation of Bezisterim in Early-stage Parkinson's Disease
Dow falls as US strikes Iran, rate-hike bets jump
3:40pm: Small cap wrap BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed the final on-treatment visit in its Phase 2 ADDRESS-LC trial evaluating...
BioVie completes final patient visit in Phase 2 Long COVID trial
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that has completed the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating bezisterim in adults with Long COVID, with topline results targeted for release before the end of September 2026. The Carson City, Nevada-based clinical-stage company is developing therapies for neurological and neurodegenerative diseases.
BioVie completes final patient visit in Phase 2 Long COVID trial
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that has completed the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating...
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
CARSON CITY, Nev., Aug. 31, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed.
BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript
BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript
Similar companies
-
Kazia Therapeutics Ltd ADR
KZIA
·
NASDAQ
Compare
-
PMGC Holdings Inc.
ELAB
·
NASDAQ
Compare
-
Can-Fite BioPharma Ltd.
CANF
·
New York Stock Exchange Arca
Compare
-
CERo Therapeutics Holdings, Inc.
CERO
·
Other OTC
Compare
-
Theriva Biologics, Inc.
TOVX
·
New York Stock Exchange Arca
Compare
-
Galmed Pharmaceuticals Ltd.
GLMD
·
NASDAQ
Compare